Huyabio concludes Phase I atrial fibrillation trial
The US Food and Drug Administration approved dose escalation in the Phase II HBI-3000-402 trial.

The US Food and Drug Administration approved dose escalation in the Phase II HBI-3000-402 trial.
The Clinical Trials Arena team also review assets in postoperative pain, cardiogenic shock, and lymphoma.
ByAs the Covid-19 pandemic stretches into its third year, the long-term effects of acute infection are beginning to become more…
ByData from the FIDELITY study will support the use of finerenone to improve cardiorenal outcomes for CKD and T2D patients.
ByAcoramidis will vie for a share of the transthyretin amyloidosis cardiomyopathy population, which Vyndaqel currently dominates.
ByThe safety profile of the oral therapy in the EXPLORER-LTE cohort was in line with the EXPLORER-HCM trial.
The company plans to report results from the clinical trial of KVD900 in the second half of next year.
Findings showed that NTLA-2001 provided a dose-dependent decline in serum TTR and attained maximal reductions by day 28.